- Home
- LYEL vs JCE Comparison
LYEL vs JCE Comparison
Compare LYEL & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- JCE
- Stock Information
- Founded
- LYEL 2018
- JCE 2007
- Country
- LYEL United States
- JCE United States
- Employees
- LYEL N/A
- JCE N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- JCE Trusts Except Educational Religious and Charitable
- Sector
- LYEL Health Care
- JCE Finance
- Exchange
- LYEL Nasdaq
- JCE Nasdaq
- Market Cap
- LYEL 207.7M
- JCE 235.3M
- IPO Year
- LYEL 2021
- JCE N/A
- Fundamental
- Price
- LYEL $0.44
- JCE $15.03
- Analyst Decision
- LYEL Sell
- JCE
- Analyst Count
- LYEL 2
- JCE 0
- Target Price
- LYEL $1.00
- JCE N/A
- AVG Volume (30 Days)
- LYEL 627.4K
- JCE 49.7K
- Earning Date
- LYEL 05-13-2025
- JCE 01-01-0001
- Dividend Yield
- LYEL N/A
- JCE 9.26%
- EPS Growth
- LYEL N/A
- JCE N/A
- EPS
- LYEL N/A
- JCE N/A
- Revenue
- LYEL $65,000.00
- JCE N/A
- Revenue This Year
- LYEL N/A
- JCE N/A
- Revenue Next Year
- LYEL N/A
- JCE N/A
- P/E Ratio
- LYEL N/A
- JCE N/A
- Revenue Growth
- LYEL N/A
- JCE N/A
- 52 Week Low
- LYEL $0.39
- JCE $11.64
- 52 Week High
- LYEL $2.80
- JCE $14.28
- Technical
- Relative Strength Index (RSI)
- LYEL 51.63
- JCE 58.05
- Support Level
- LYEL $0.39
- JCE $14.84
- Resistance Level
- LYEL $0.43
- JCE $15.22
- Average True Range (ATR)
- LYEL 0.03
- JCE 0.30
- MACD
- LYEL 0.00
- JCE -0.02
- Stochastic Oscillator
- LYEL 83.39
- JCE 60.17
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.